Research programme : Anti-S100A9 monoclonal antibodies - InflammatoRx

Drug Profile

Research programme : Anti-S100A9 monoclonal antibodies - InflammatoRx

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InflammatoRx
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action S100 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Neurodegenerative disorders

Most Recent Events

  • 27 Sep 2016 Research programme : Anti-S100A9 monoclonal antibodies - InflammatoRx is available for licensing as of 27 Sep 2016. http://www.inflammatorx.com/#
  • 27 Sep 2016 Preclinical trials in Inflammation in Canada (unspecified route) (InflammatoRx pipeline, September 2016)
  • 27 Sep 2016 Preclinical trials in Neurodegenerative disorders in Canada (unspecified route) prior to September 2016 (InflammatoRx pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top